Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration

Mona Bhargava; Rama Rajagopal; Radhika Natarajan; Rachapalle Reddi Sudhir; Saket Shashikant Benurwar; Raj Shekhar Paul

doi:doi:10.11648/j.ijovs.20220702.13

| Peer-Reviewed

Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration

Mona Bhargava, Rama Rajagopal, Radhika Natarajan, Rachapalle Reddi Sudhir, Saket Shashikant Benurwar, Raj Shekhar Paul

Published in International Journal of Ophthalmology & Visual Science (Volume 7, Issue 2)

Received: 6 April 2022 Accepted: 2 May 2022 Published: 12 May 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

A retrospective interventional study involving 15 eyes of 10 patients with pellucid marginal degeneration (PMD) were treated with collagen cross linking (CXL) to evaluate itslong term effects on such patients. The eyes were divided as per riboflavin used namely hypo-osmolar, HPMC (hydroxy propyl methyl cellulose), iso-osmolar into group A, B and C respectively. Visual acuity, retinoscopic refraction, corneal topography, tomography and pachymetry were examined before and every six months after surgery for the first two years and then annually. logMAR UCVA (uncorrected visual acuity) and BCVA (best corrected visual acuity) with spectacles at 6 months and at final follow-up showed improvement in all groups, which were significant in group C. There was no significant difference in the pre and post-op spherical equivalent (P = 0.38) and the mean cylinder decreased by 0.53 ± 0.81 D (P = 0.19) which was not significant. Keratometric astigmatism decreased by 1.13 D (P = 0.2) measured by Scheimpflug imaging and by 1.4 D (P = 0.13) as measured by topography. Maximum keratometry (Kmax) showed a reduction from 50.62 ± 5.2 to 50.23 ± 4.9 (P = 0.07) at 6 months and 48.95 ± 4.7 (P = 0.09) at final follow-up. None of the treated eyes developed side effect of notable severity. Collagen cross linking is a safe and effective method to prevent progression in PMD. Stability of astigmatism, keratometric parameters and improvement in BCVA in our study indicates the efficacy of CXL to prevent progression in PMD.

Published in	International Journal of Ophthalmology & Visual Science (Volume 7, Issue 2)
DOI	10.11648/j.ijovs.20220702.13
Page(s)	57-64
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Pellucid Marginal Degeneration, Collagen Cross Linking, Pentacam

References

[1]	Krachmer JH. Pellucid marginal degeneration. Arch Ophthalmol 1978; 96: 1217-21.
[2]	Walker RN, Khachikian SS, Belin MW. Scheimpflug photographic diagnosis of pellucid marginal degeneration. Cornea 2008; 27: 963-6.
[3]	Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. Surv Ophthalmol 1984; 28: 293-322.
[4]	Klyce SD. Computer-assisted corneal topography: high resolution graphic presentation and analysis of keratoscopy. Invest Ophthalmol Vis Sci 1984; 25: 1426-35.
[5]	Kompella V. B., Aasuri M. K., Rao G. N. Management of pellucid marginal corneal degeneration with rigid gas permeable contact lenses. CLAO Journal. 2002; 28 (3): 140-145.
[6]	Biswas S., Brahma A., Tromans C., Ridgway A. Management of pellucid marginal corneal degeneration. Eye. 2000; 14 (4): 629–634.
[7]	Mularoni A., Torreggiani A., di Biase A., Laffi G. L., Tassinari G. Conservative treatment of early and moderate pellucid marginal degeneration: a new refractive approach with intracorneal rings. Ophthalmology. 2005; 112 (4): 660–666.
[8]	Rasheed K, Rabinowitz YS. Surgical treatment of advanced pellucid marginal degeneration. Ophthalmology 2000; 107: 1836–1840.
[9]	G. A., Macsai M. S., Krachmer J. H. The results of penetrating keratoplasty for pellucid marginal corneal degeneration. American Journal of Ophthalmology. 1990; 110 (2): 149-152.
[10]	Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen cross linking for the treatment of keratoconus. J Cataract Refract Surg 2003; 135: 620-7.
[11]	Spadea L. Corneal collagen cross-linking with riboflavin and UVA irradiation in pellucid marginal degeneration. J Refract Surg. 2010; 26: 375–7.
[12]	Oltulu, R., Satirtav, G., Donbaloglu, M., Kerimoglu, H., Özkagnici, A., & Karaibrahimoglu, A. (2014). Intraoperative corneal thickness monitoring during corneal collagen crosslinking with isotonic riboflavin solution with and without dextran. Cornea, 33 (11), 1164-1167.
[13]	Hafezi F., Kanellopoulos J., Wiltfang R., Seiler T. Corneal collagen cross linking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. Journal of Cataract & Refractive Surgery. 2007; 33 (12): 2035–2040.
[14]	Krueger R. R., Ramos-Esteban J. C., Kanellopoulos A. J. Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy: laboratory investigation and first clinical case. Journal of Refractive Surgery. 2008; 24 (7): 730–736.
[15]	Wollensak G. Corneal collagen cross-linking: New horizons. Expert Rev Ophthalmol 2010; 5: 201-15.
[16]	Ithar M, Beshtawi. M, ClareO’DonnellHemaRadhakrishnan. Biomechanical properties of corneal tissue after ultraviolet-A–riboflavin crosslinking. Journal of cataract and refractive surgery. 2013; 39: 451-462.
[17]	Stein R, Stein R, Honours B. Corneal collagen crosslinking: A major breakthrough in the management of keratoconus, pellucid marginal degeneration, and ectasia after LASIK. Ophthalmology rounds 2011; 9: 1.
[18]	Ziad Hassan, Gabor Nemeth, Laszlo Modis, EszterSzalai and Andras Berta. Collagen cross-linking in the treatment of pellucid marginal degeneration. Indian J Ophthalmol. 2014 Mar; 62 (3): 367–370.
[19]	Bayraktar S, Cebeci Z, Oray M, Alparslan N Corneal Collagen Cross-Linking in Pellucid Marginal Degeneration: 2 Patients, 4 Eyes. Case Rep Ophthalmol Med. 2015; 2015: 840687.
[20]	Bashir Mamoosa, Hassan Razmjoo, Alireza Peyman, Alireza Ashtari, Iman Ghafouri, and Amir Ghorbanzadeh Moghaddam. Short-term result of collagen crosslinking in pellucid marginal degeneration. Adv Biomed Res. 2016; 5: 194-196.
[21]	Greenstein SA, Shah VP, Fry KL, Hersh PS. Corneal thickness changes after corneal collagen crosslinking for keratoconus and corneal ectasia: one-year results. J Cataract Refract Surg. 2011; 37 (4): 691-700.
[22]	Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagencross- linking with riboflavin and ultraviolet-A light in keratoconus: long- term results. J Cataract Refract Surg 2008; 34: 796–801.
[23]	Grewal DS, Brar GS, Jain R, Sood V, Singla M, Grewal SPS. Corneal collagen crosslinking using riboflavin and ultraviolet-A light for keratoconus; one-year analysis using Scheimpflug imaging. J Cataract Refract Surg 2009; 35: 425-432.
[24]	Corbett MC, Prydal JI, Verma S, Oliver KM, Pande M, Marshall J. An in vivo investigation of the structures responsible for corneal haze after photorefractive keratectomy and their effect on visual function. Ophthalmology 1996; 103: 1366–1380.
[25]	Padmanabhan P, Rachapalle R, Rajagopal R et al. Corneal Collagen cross-linking for keratoconus in pediatric patients—long-term results. Cornea 2017; 36: 138–142.
[26]	Vimalin J, Gupta N, Jambulingam M et al. The effect of riboflavin-UV- A treatment on corneal limbal epithelial cells—a study on human cadaver eyes. Cornea. 2012; 31: 1052–1059.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mona Bhargava, Rama Rajagopal, Radhika Natarajan, Rachapalle Reddi Sudhir, Saket Shashikant Benurwar, et al. (2022). Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration. International Journal of Ophthalmology & Visual Science, 7(2), 57-64. https://doi.org/10.11648/j.ijovs.20220702.13

Copy | Download

ACS Style

Mona Bhargava; Rama Rajagopal; Radhika Natarajan; Rachapalle Reddi Sudhir; Saket Shashikant Benurwar, et al. Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration. Int. J. Ophthalmol. Vis. Sci. 2022, 7(2), 57-64. doi: 10.11648/j.ijovs.20220702.13

Copy | Download

AMA Style

Mona Bhargava, Rama Rajagopal, Radhika Natarajan, Rachapalle Reddi Sudhir, Saket Shashikant Benurwar, et al. Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration. Int J Ophthalmol Vis Sci. 2022;7(2):57-64. doi: 10.11648/j.ijovs.20220702.13

Copy | Download

@article{10.11648/j.ijovs.20220702.13,
  author = {Mona Bhargava and Rama Rajagopal and Radhika Natarajan and Rachapalle Reddi Sudhir and Saket Shashikant Benurwar and Raj Shekhar Paul},
  title = {Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration},
  journal = {International Journal of Ophthalmology & Visual Science},
  volume = {7},
  number = {2},
  pages = {57-64},
  doi = {10.11648/j.ijovs.20220702.13},
  url = {https://doi.org/10.11648/j.ijovs.20220702.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20220702.13},
  abstract = {A retrospective interventional study involving 15 eyes of 10 patients with pellucid marginal degeneration (PMD) were treated with collagen cross linking (CXL) to evaluate itslong term effects on such patients. The eyes were divided as per riboflavin used namely hypo-osmolar, HPMC (hydroxy propyl methyl cellulose), iso-osmolar into group A, B and C respectively. Visual acuity, retinoscopic refraction, corneal topography, tomography and pachymetry were examined before and every six months after surgery for the first two years and then annually. logMAR UCVA (uncorrected visual acuity) and BCVA (best corrected visual acuity) with spectacles at 6 months and at final follow-up showed improvement in all groups, which were significant in group C. There was no significant difference in the pre and post-op spherical equivalent (P = 0.38) and the mean cylinder decreased by 0.53 ± 0.81 D (P = 0.19) which was not significant. Keratometric astigmatism decreased by 1.13 D (P = 0.2) measured by Scheimpflug imaging and by 1.4 D (P = 0.13) as measured by topography. Maximum keratometry (Kmax) showed a reduction from 50.62 ± 5.2 to 50.23 ± 4.9 (P = 0.07) at 6 months and 48.95 ± 4.7 (P = 0.09) at final follow-up. None of the treated eyes developed side effect of notable severity. Collagen cross linking is a safe and effective method to prevent progression in PMD. Stability of astigmatism, keratometric parameters and improvement in BCVA in our study indicates the efficacy of CXL to prevent progression in PMD.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration
AU  - Mona Bhargava
AU  - Rama Rajagopal
AU  - Radhika Natarajan
AU  - Rachapalle Reddi Sudhir
AU  - Saket Shashikant Benurwar
AU  - Raj Shekhar Paul
Y1  - 2022/05/12
PY  - 2022
N1  - https://doi.org/10.11648/j.ijovs.20220702.13
DO  - 10.11648/j.ijovs.20220702.13
T2  - International Journal of Ophthalmology & Visual Science
JF  - International Journal of Ophthalmology & Visual Science
JO  - International Journal of Ophthalmology & Visual Science
SP  - 57
EP  - 64
PB  - Science Publishing Group
SN  - 2637-3858
UR  - https://doi.org/10.11648/j.ijovs.20220702.13
AB  - A retrospective interventional study involving 15 eyes of 10 patients with pellucid marginal degeneration (PMD) were treated with collagen cross linking (CXL) to evaluate itslong term effects on such patients. The eyes were divided as per riboflavin used namely hypo-osmolar, HPMC (hydroxy propyl methyl cellulose), iso-osmolar into group A, B and C respectively. Visual acuity, retinoscopic refraction, corneal topography, tomography and pachymetry were examined before and every six months after surgery for the first two years and then annually. logMAR UCVA (uncorrected visual acuity) and BCVA (best corrected visual acuity) with spectacles at 6 months and at final follow-up showed improvement in all groups, which were significant in group C. There was no significant difference in the pre and post-op spherical equivalent (P = 0.38) and the mean cylinder decreased by 0.53 ± 0.81 D (P = 0.19) which was not significant. Keratometric astigmatism decreased by 1.13 D (P = 0.2) measured by Scheimpflug imaging and by 1.4 D (P = 0.13) as measured by topography. Maximum keratometry (Kmax) showed a reduction from 50.62 ± 5.2 to 50.23 ± 4.9 (P = 0.07) at 6 months and 48.95 ± 4.7 (P = 0.09) at final follow-up. None of the treated eyes developed side effect of notable severity. Collagen cross linking is a safe and effective method to prevent progression in PMD. Stability of astigmatism, keratometric parameters and improvement in BCVA in our study indicates the efficacy of CXL to prevent progression in PMD.
VL  - 7
IS  - 2
ER  -

Copy | Download

Author Information

Mona Bhargava

Department of Cornea and Refractive Surgery, Aditya Birla Sankara Nethralaya, Kolkata, India
Rama Rajagopal

Department of Cornea and Refractive Surgery, Sankara Nethralaya, Chennai, India
Radhika Natarajan

Department of Cornea and Refractive Surgery, Sankara Nethralaya, Chennai, India
Rachapalle Reddi Sudhir

Department of Cornea and Refractive Surgery, Sankara Nethralaya, Chennai, India
Saket Shashikant Benurwar

Department of Cornea and Refractive Surgery, Aditya Birla Sankara Nethralaya, Kolkata, India
Raj Shekhar Paul

Department of Cornea and Refractive Surgery, Aditya Birla Sankara Nethralaya, Kolkata, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mona Bhargava, Rama Rajagopal, Radhika Natarajan, Rachapalle Reddi Sudhir, Saket Shashikant Benurwar, et al. (2022). Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration. International Journal of Ophthalmology & Visual Science, 7(2), 57-64. https://doi.org/10.11648/j.ijovs.20220702.13

Copy | Download

ACS Style

Mona Bhargava; Rama Rajagopal; Radhika Natarajan; Rachapalle Reddi Sudhir; Saket Shashikant Benurwar, et al. Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration. Int. J. Ophthalmol. Vis. Sci. 2022, 7(2), 57-64. doi: 10.11648/j.ijovs.20220702.13

Copy | Download

AMA Style

Mona Bhargava, Rama Rajagopal, Radhika Natarajan, Rachapalle Reddi Sudhir, Saket Shashikant Benurwar, et al. Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration. Int J Ophthalmol Vis Sci. 2022;7(2):57-64. doi: 10.11648/j.ijovs.20220702.13

Copy | Download

@article{10.11648/j.ijovs.20220702.13,
  author = {Mona Bhargava and Rama Rajagopal and Radhika Natarajan and Rachapalle Reddi Sudhir and Saket Shashikant Benurwar and Raj Shekhar Paul},
  title = {Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration},
  journal = {International Journal of Ophthalmology & Visual Science},
  volume = {7},
  number = {2},
  pages = {57-64},
  doi = {10.11648/j.ijovs.20220702.13},
  url = {https://doi.org/10.11648/j.ijovs.20220702.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20220702.13},
  abstract = {A retrospective interventional study involving 15 eyes of 10 patients with pellucid marginal degeneration (PMD) were treated with collagen cross linking (CXL) to evaluate itslong term effects on such patients. The eyes were divided as per riboflavin used namely hypo-osmolar, HPMC (hydroxy propyl methyl cellulose), iso-osmolar into group A, B and C respectively. Visual acuity, retinoscopic refraction, corneal topography, tomography and pachymetry were examined before and every six months after surgery for the first two years and then annually. logMAR UCVA (uncorrected visual acuity) and BCVA (best corrected visual acuity) with spectacles at 6 months and at final follow-up showed improvement in all groups, which were significant in group C. There was no significant difference in the pre and post-op spherical equivalent (P = 0.38) and the mean cylinder decreased by 0.53 ± 0.81 D (P = 0.19) which was not significant. Keratometric astigmatism decreased by 1.13 D (P = 0.2) measured by Scheimpflug imaging and by 1.4 D (P = 0.13) as measured by topography. Maximum keratometry (Kmax) showed a reduction from 50.62 ± 5.2 to 50.23 ± 4.9 (P = 0.07) at 6 months and 48.95 ± 4.7 (P = 0.09) at final follow-up. None of the treated eyes developed side effect of notable severity. Collagen cross linking is a safe and effective method to prevent progression in PMD. Stability of astigmatism, keratometric parameters and improvement in BCVA in our study indicates the efficacy of CXL to prevent progression in PMD.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Long Term Results of Collagen Cross Linking in Pellucid Marginal Degeneration
AU  - Mona Bhargava
AU  - Rama Rajagopal
AU  - Radhika Natarajan
AU  - Rachapalle Reddi Sudhir
AU  - Saket Shashikant Benurwar
AU  - Raj Shekhar Paul
Y1  - 2022/05/12
PY  - 2022
N1  - https://doi.org/10.11648/j.ijovs.20220702.13
DO  - 10.11648/j.ijovs.20220702.13
T2  - International Journal of Ophthalmology & Visual Science
JF  - International Journal of Ophthalmology & Visual Science
JO  - International Journal of Ophthalmology & Visual Science
SP  - 57
EP  - 64
PB  - Science Publishing Group
SN  - 2637-3858
UR  - https://doi.org/10.11648/j.ijovs.20220702.13
AB  - A retrospective interventional study involving 15 eyes of 10 patients with pellucid marginal degeneration (PMD) were treated with collagen cross linking (CXL) to evaluate itslong term effects on such patients. The eyes were divided as per riboflavin used namely hypo-osmolar, HPMC (hydroxy propyl methyl cellulose), iso-osmolar into group A, B and C respectively. Visual acuity, retinoscopic refraction, corneal topography, tomography and pachymetry were examined before and every six months after surgery for the first two years and then annually. logMAR UCVA (uncorrected visual acuity) and BCVA (best corrected visual acuity) with spectacles at 6 months and at final follow-up showed improvement in all groups, which were significant in group C. There was no significant difference in the pre and post-op spherical equivalent (P = 0.38) and the mean cylinder decreased by 0.53 ± 0.81 D (P = 0.19) which was not significant. Keratometric astigmatism decreased by 1.13 D (P = 0.2) measured by Scheimpflug imaging and by 1.4 D (P = 0.13) as measured by topography. Maximum keratometry (Kmax) showed a reduction from 50.62 ± 5.2 to 50.23 ± 4.9 (P = 0.07) at 6 months and 48.95 ± 4.7 (P = 0.09) at final follow-up. None of the treated eyes developed side effect of notable severity. Collagen cross linking is a safe and effective method to prevent progression in PMD. Stability of astigmatism, keratometric parameters and improvement in BCVA in our study indicates the efficacy of CXL to prevent progression in PMD.
VL  - 7
IS  - 2
ER  -

Copy | Download